Eli Lilly (LLY) Q3 2026 Earnings Deep Dive: Mounjaro, Foundayo & The $4.2B Charge

AI-generated source summary

Eli Lilly (LLY) is experiencing a significant divergence between its soaring stock price, currently at an all-time high of $1,288, and its declining earnings per share (EPS). The company forecasts revenue growth of 26-29% for Q3 2026, translating to $22.1-$22.6 billion, with adjusted EPS projected to drop to $5.38-$6.61. This is attributed to a $4.20 billion acquired IPR&D charge from strategic acquisitions and a 13% decline in realized prices, particularly in China, despite a 60% surge in volume for Q2. The company's weight-loss drugs, Mounjaro and Zepbound, are the primary revenue drivers, generating $14.87 billion combined in Q2, representing 65% of total revenue. Mounjaro's success in the global weight-loss market, where Lilly and Novo Nordisk dominate with 97% share in 2025, is a key factor. However, concerns exist regarding potential competition from oral GLP-1 drugs, which could disrupt the market dominance of injectables. Analysts' price targets show a wide dispersion, from a high of $1,600 suggesting strong upside potential, to a low of $930 indicating a significant downside risk of 28%. The market is pricing in a 50% premium on forward earnings, implying a 33x P/E ratio, which requires sustained revenue growth of over 20% annually to justify. Key Q3 risks include international pricing pressure, potential stagnation of Foundayo sales, Retatrutide FDA filing delays, competitive generics in China, and FY2026 growth deceleration. For long-term holders, the 2028 pipeline is seen as intact, suggesting a 'hold' strategy. Traders are advised caution due to asymmetric downside risk, and new money should wait for a pullback entry point, likely between $1,150 and $1,200.

AI-generated summary based on the source content.